Indole

Indole

SCHEMBL1614937

CCC(=O)O.c1ccc2[nH]ccc2c1

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.63
CA1 P00915 1/20 0.63
CA2 P00918 1/20 0.63
ITGB2 P05107 1/20 0.63
ICAM1 P05362 1/20 0.63
ITGAL P20701 1/20 0.63
CA4 P22748 1/20 0.63
CA6 P23280 1/20 0.63
AHR P35869 1/20 0.63
ADK P55263 1/20 0.63
CTNNB1 P35222 2/20 0.47
WNT3A P56704 2/20 0.47
ESR1 P03372 1/20 0.46
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
ENPP2 Q13822 1/20 0.44
HSD17B10 Q99714 1/20 0.44
NPC1 O15118 2/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Indole SCHEMBL31188952 1.00 TRPA1 (0.63) TRPA1CA1CA2ITGB2ICAM1
Indole SCHEMBL28129119 1.00 TRPA1 (0.63) TRPA1CA1CA2ITGB2ICAM1
Indole SCHEMBL20529585 0.92 TRPA1 (0.53) TRPA1CA1CA2ITGB2ICAM1
Indole SCHEMBL28833831 0.89 TRPA1 (0.63) TRPA1CA1CA2ITGB2ICAM1
Indole SCHEMBL2347749 0.88 TRPA1 (0.57) TRPA1CA1CA2ITGB2ICAM1
Indole SCHEMBL412813 0.88 TRPA1 (0.57) TRPA1CA1CA2ITGB2ICAM1
Indole SCHEMBL1714302 0.87 TRPA1 (0.61) TRPA1CA1CA2ITGB2ICAM1
Indole SCHEMBL1714414 0.87 TRPA1 (0.65) TRPA1CA1CA2ITGB2ICAM1
Indole SCHEMBL6835663 0.87 TRPA1 (0.65) TRPA1CA1CA2ITGB2ICAM1
Indole SCHEMBL15552 0.86 TRPA1 (0.71) TRPA1CA1CA2ITGB2ICAM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 550 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12633376-B2 System and method for risk assessment of autism spectrum disorder TATA CONSULTANCY SERVICES LIMITED (IN) 2026-05-19 US claimed
US-20260053887-A1 Methods and Kits to Prevent And/Or Treat Cardiac Disorders UNIV IOWA RES FOUND (US) 2026-02-26 US claimed
US-20250367246-A1 IMMUNOMODULATORY COMPOSITIONS COMPRISING MICROBIAL ENTITIES SOLAREA BIO INC (US) 2025-12-04 US claimed
US-20250356948-A1 SYSTEM AND METHOD FOR RISK ASSESSMENT OF AUTISM SPECTRUM DISORDER TATA CONSULTANCY SERVICES LIMITED (IN) 2025-11-20 US claimed
US-12440523-B2 Immunomodulatory compositions comprising microbial entities SOLAREA BIO, INC. (US) 2025-10-14 US claimed
CN-119951426-A Double-network gel microsphere with pH response and preparation method and application thereof 合肥工业大学 2025-05-09 CN claimed
CN-118931933-A Recombinant vector for biosynthesis of indopropionic acid, engineering bacterium and application thereof 镇江市天益生物科技有限公司 2024-11-12 CN claimed
EP-4452287-A2 IMMUNOMODULATORY COMPOSITIONS COMPRISING MICROBIAL ENTITIES Solarea Bio, Inc. (US) 2024-10-30 EP claimed
CN-118831071-A Sequential multistage targeted delivery system for repairing intestinal barrier and preparation method thereof 大连理工大学 2024-10-25 CN claimed
CN-118696825-A Liaodong clove immature embryo regeneration method 青海省农林科学院 2024-09-27 CN claimed
US-20050197253-A1 Methods for improving growth and crop productivity of plants by adjusting plant hormone levels, ratios and/or co-factors BANK OF AMERICA, NA 2005-09-08 US claimed
WO-2005021715-A2 METHODS FOR IMPROVING GROWTH AND CROP PRODUCTIVITY OF PLANTS BY ADJUSTING PLANT HORMONE LEVELS, RATIOS AND/OR CO-FACTORS STOLLER ENTERPRISES, INC. (US) 2005-03-10 WO claimed
WO-2005018319-A2 SUPPRESSING PLANT PATHOGENS AND PESTS WITH APPLIED OR INDUCED AUXINS STOLLER ENTERPRISES, INC. (US) 2005-03-03 WO claimed
US-20050043177-A1 Controlling plant pathogens and pests with applied or induced auxins BANK OF AMERICA, NA 2005-02-24 US claimed
EP-1372571-A2 METHOD AND COMPOSITIONS FOR OPTIMIZING BLOOD AND TISSUE STABILITY OF CAMPTOTHECIN AND OTHER ALBUMIN-BINDING THERAPEUTIC COMPOUNDS New Century Pharmaceuticals, Inc. (US) 2004-01-02 EP claimed
US-20020193318-A1 Methods and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds NEW CENTURY PHARMACEUTICALS, INC. 2002-12-19 US claimed
WO-2002074246-A2 METHOD AND COMPOSITIONS FOR OPTIMIZING BLOOD AND TISSUE STABILITY OF CAMPTOTHECIN AND OTHER ALBUMIN-BINDING THERAPEUTIC COMPOUNDS NEW CENTURY PHARMACEUTICALS, INC. (US) 2002-09-26 WO claimed
EP-1171603-A1 A PROCESS FOR PRODUCING PURIFIED BIOLOGICALLY ACTIVE, FREE FORM OF RECOMBINANT HUMAN INTERFERON GAMMA Vyas, Sharad Kumar (IN) 2002-01-16 EP claimed
WO-2001057218-A1 A PROCESS FOR PRODUCING PURIFIED BIOLOGICALLY ACTIVE, FREE FORM OF RECOMBINANT HUMAN INTERFERON GAMMA VYAS SHARAD KUMAR (IN) 2001-08-09 WO claimed
EP-0175577-A2 Microchemiluminescent assay system Kiel, Jonathan L (US) 1986-03-26 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12633376-B2 System and method for risk assessment of autism spectrum disorder TPH1, KYNU, TPH2 TRPA1 2104/4885CA1 2995/4885CA2 3169/4885
US-20020193318-A1 Methods and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds ALB, TYMP, SHBG TRPA1 4851/4885CA1 3364/4885CA2 4399/4885
US-20260053887-A1 Methods and Kits to Prevent And/Or Treat Cardiac Disorders KYNU, AADAT, TPH1 TRPA1 1052/4885CA1 2837/4885CA2 2711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.